Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PLA2G4A |
| Gene Name: | PLA2G4A |
| Protein Full Name: | Cytosolic phospholipase A2 |
| Alias: | CPLA2; CPLA2-alpha; PA24; PA24A; Phosphatidylcholine 2-acylhydrolase; Phospholipase A2, group IVA (cytosolic, calcium-dependent); PLA2G4 |
| Mass (Da): | 85211 |
| Number AA: | 749 |
| UniProt ID: | P47712 |
| Locus ID: | 5321 |
| COSMIC ID: | PLA2G4A |
| Gene location on chromosome: | 1q31.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20212 |
| Percent of cancer specimens with mutations: | 0.93 |
| Normal role description: | This phospholipase is activated by increases in intracellular calcium. It generates free-fatty acids such as arachidonic acid by cleaving phosphatidylcholine. These are all considered second and third messengers in cellular signalling. Upregulation of PLA2G4A has been demonstrated in many cancer systems. Oncogenesis mediated through increased COX-2 angiogenesis, PPARdelta signalling, and PGE2 signalling. |